Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai Pharmaceutical And Japan Suzuken Establish Joint Venture

This article was originally published in PharmAsia News

Executive Summary

Shanghai Pharmaceutical Co. and Suzuken, Japan's second largest pharmaceutical wholesaler, have officially launched their 50-50 venture. According to Shanghai Pharmaceutical, the new Shanghai-Suzuken company aims to become the first brand name in China to provide pharmaceutical distribution services. In the first year, sales revenue and net profits are estimated to increase by 20 and 30 percent respectively compared to its previous entity. This venture's rate of return tops the local pharmaceutical business equity transfer and Shanghai Pharmaceutical is confident that the collaboration will maximize its short- to long-term interests. Suzuken will introduce its established Japanese products, sales support system, management consulting system and other value-added services to enhance the new firm's competitiveness. (Click here for more - Chinese Language)

You may also be interested in...



Leaner Kabi Drives Higher Savings Goal For Fresenius, China ‘Soft’ In 2024

Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.

French Agency Sets Up New Body To Advise On Biosimilar Substitution

The new committee, which will initially be in place for a year, will advise the French drug regulator when it is preparing its opinions on substitution in specific biosimilar product groups.

New EU Regulation Extending IVD Deadlines Expected In April

IVD manufacturers look set to be granted up to 18 more months to comply with the EU IVD Regulation very soon.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel